Publications by authors named "M Gorniak"
Article Synopsis
- * Inhibition of ATGL using the human-specific inhibitor NG497 led to an increase in lipid droplet size and number in beta cells under glucose-sufficient conditions, while in alpha cells, the effect was more pronounced under fasting conditions, indicating ATGL's role in hormone secretion in both cell types.
- * Acute inhibition of ATGL reduced glucose-stimulated insulin secretion, particularly first-phase secretion, but to a lesser extent than chronic downregulation; NG497 also significantly lowered glucagon secretion at low
Depression is a known stroke risk factor, but its influence on stroke course depending on gender and age is not clearly defined. The purpose of this study was to determine the impact of previously diagnosed depression on early and one-year mortality in patients with acute ischemic stroke (IS) in relation to gender, age, and concomitant diseases. This study was based on the registry created from the public health insurer in Poland (2009-2020).
View Article and Find Full Text PDFMeasurable residual disease (MRD) testing is an essential aspect of disease prognostication in acute lymphoblastic leukaemia (ALL) and informs clinical decisions. The depth of MRD clearance is highly relevant and requires assays with sufficient sensitivity. Austin Pathology is one of the few laboratories in Australia currently utilising a fully validated and National Association of Testing Authorities (NATA)-accredited ultrasensitive next-generation sequencing (NGS) platform for MRD monitoring in ALL.
View Article and Find Full Text PDFObjective: The objective of this study is to investigate changes in willingness for total knee replacement (TKR) surgery following a randomised control trial (RCT) of an osteoarthritis management program, and to extrapolate orthopaedic cost consequences for private health insurers (PHI).
Methods: Willingness for surgery data from the RCT is analysed using a multinomial logistic regression model. A decision analytic model is used to conduct a break-even cost benefit analysis of the intervention from a PHI payer perspective.